{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:41:49Z","timestamp":1783579309531,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","injuryjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Injury"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.injury.2025.112357","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T11:44:59Z","timestamp":1745927099000},"page":"112357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The role of Bisphosphonates in the prevention and treatment of Heterotopic Ossification following Spinal Cord Injury: A systematic review"],"prefix":"10.1016","volume":"56","author":[{"given":"Avraam","family":"Ploumis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8865-8939","authenticated-orcid":false,"given":"Athanasios","family":"Kefalas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George I.","family":"Vasileiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5509-2224","authenticated-orcid":false,"given":"Eleni","family":"Kougkouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Markou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Dimakopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Doulgeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3639-9274","authenticated-orcid":false,"given":"Dimitrios N.","family":"Varvarousis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.injury.2025.112357_bib0001","first-page":"151","article-title":"A comparison of heterotopic ossification treatment within the traumatic brain and spinal cord injured population: An evidence based systematic review","volume":"28","author":"Aubut","year":"2011","journal-title":"NeuroRehabilitation"},{"issue":"2","key":"10.1016\/j.injury.2025.112357_bib0002","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1179\/2045772314Y.0000000213","article-title":"Association between alendronate, serum alkaline phosphatase level, and heterotopic ossification in individuals with spinal cord injury","volume":"38","author":"Ploumis","year":"2015","journal-title":"J Spinal Cord Med"},{"issue":"7","key":"10.1016\/j.injury.2025.112357_bib0003","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.sc.3101309","article-title":"Neurogenic heterotopic ossification in spinal cord injury","volume":"40","author":"van Kuijk","year":"2002","journal-title":"Spinal Cord"},{"issue":"7","key":"10.1016\/j.injury.2025.112357_bib0004","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/sc.2009.175","article-title":"A systematic review of the therapeutic interventions for heterotopic ossification after spinal cord injury","volume":"48","author":"Teasell","year":"2010","journal-title":"Spinal Cord"},{"key":"10.1016\/j.injury.2025.112357_bib0005","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.injury.2025.112357_bib0006","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/jech.52.6.377","article-title":"The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions","volume":"52","author":"Downs","year":"1998","journal-title":"J Epidemiol Community Health"},{"issue":"10","key":"10.1016\/j.injury.2025.112357_bib0007","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.sc.3101761","article-title":"Amino-bisphosphonates in heterotopic ossification: first experience in five consecutive cases","volume":"43","author":"Schuetz","year":"2005","journal-title":"Spinal Cord"},{"key":"10.1016\/j.injury.2025.112357_bib0008","first-page":"581","article-title":"A double-blind study of EHDP on heterotopic ossification after spinal cord injury using placebo","volume":"16","author":"Ono","year":"1988","journal-title":"Rinsho Hyoka"},{"issue":"5","key":"10.1016\/j.injury.2025.112357_bib0009","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2106\/00004623-197658050-00019","article-title":"Disodium etidronate in the prevention of postoperative recurrence of heterotopic ossification in spinal-cord injury patients","volume":"58","author":"Stover","year":"1976","journal-title":"J Bone Joint Surg Am"},{"issue":"4-5","key":"10.1016\/j.injury.2025.112357_bib0010","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0221-8747(81)90050-3","article-title":"Heterotopic ossification following hip replacement or spinal cord injury. Two clinical studies with EHDP","volume":"3","author":"Finerman","year":"1981","journal-title":"Metab Bone Dis Relat Res"},{"issue":"10","key":"10.1016\/j.injury.2025.112357_bib0011","first-page":"660","article-title":"Intravenous disodium etidronate therapy in spinal cord injury patients with heterotopic ossification","volume":"31","author":"Banovac","year":"1993","journal-title":"Paraplegia"},{"issue":"1","key":"10.1016\/j.injury.2025.112357_bib0012","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1080\/10790268.1997.11719457","article-title":"Treatment of heterotopic ossification after spinal cord injury","volume":"20","author":"Banovac","year":"1997","journal-title":"J Spinal Cord Med"},{"issue":"3","key":"10.1016\/j.injury.2025.112357_bib0013","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/sj.sc.3100380","article-title":"Evaluation and management of heterotopic ossification in patients with spinal cord injury","volume":"35","author":"Banovac","year":"1997","journal-title":"Spinal Cord"},{"issue":"1","key":"10.1016\/j.injury.2025.112357_bib0014","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/10790268.2000.11753507","article-title":"The effect of etidronate on late development of heterotopic ossification after spinal cord injury","volume":"23","author":"Banovac","year":"2000","journal-title":"J Spinal Cord Med"},{"issue":"176","key":"10.1016\/j.injury.2025.112357_bib0015","first-page":"197","article-title":"Diphosphonate treatment for heterotopic ossification in spinal cord injury patients","author":"Garland","year":"1983","journal-title":"Clin Orthop Relat Res"},{"issue":"1","key":"10.1016\/j.injury.2025.112357_bib0016","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/01952307.1987.11719626","article-title":"Resection of heterotopic ossification and Didronel therapy\u2013regaining wheelchair independence in the spinal cord injured patient","volume":"10","author":"Subbarao","year":"1987","journal-title":"J Am Paraplegia Soc"},{"issue":"9","key":"10.1016\/j.injury.2025.112357_bib0017","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.injury.2025.112357_bib0018","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bone.2007.09.001","article-title":"Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis","volume":"42","author":"Delmas","year":"2008","journal-title":"Bone"},{"issue":"8","key":"10.1016\/j.injury.2025.112357_bib0019","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.injury.2025.112357_bib0020","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1210\/jc.2006-2013","article-title":"Alendronate prevents bone loss in patients with acute spinal cord injury: a randomized, double-blind, placebo-controlled study","volume":"92","author":"Gilchrist","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.injury.2025.112357_bib0021","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0003-9993(99)90133-8","article-title":"Intravenous pamidronate attenuates bone density loss after acute spinal cord injury","volume":"80","author":"Nance","year":"1999","journal-title":"Arch Phys Med Rehabil"},{"issue":"10","key":"10.1016\/j.injury.2025.112357_bib0022","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.injury.2025.112357_bib0023","first-page":"968","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid","volume":"91","author":"Dimopoulos","year":"2006","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.injury.2025.112357_bib0024","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"18","key":"10.1016\/j.injury.2025.112357_bib0025","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"issue":"7648","key":"10.1016\/j.injury.2025.112357_bib0026","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/bmj.39507.551644.BE","article-title":"Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study","volume":"336","author":"Sorensen","year":"2008","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.injury.2025.112357_bib0027","first-page":"712","article-title":"Yearly zoledronic acid in postmenopausal osteoporosis","volume":"357","author":"Karam","year":"2007","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.injury.2025.112357_bib0028","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.injury.2025.112357_bib0029","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1359\/jbmr.070609","article-title":"Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study","volume":"22","author":"Chapurlat","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.injury.2025.112357_bib0030","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4158\/EP.12.1.48","article-title":"Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature","volume":"12","author":"Maalouf","year":"2006","journal-title":"Endocr Pract"},{"issue":"3","key":"10.1016\/j.injury.2025.112357_bib0031","first-page":"346","article-title":"Alendronate and risedronate: reports of severe bone, joint, and muscle pain","volume":"165","author":"Wysowski","year":"2005","journal-title":"Arch Intern Med"},{"issue":"12","key":"10.1016\/j.injury.2025.112357_bib0032","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/sj.sc.3101628","article-title":"Prevention of heterotopic ossification after spinal cord injury with COX-2 selective inhibitor (rofecoxib)","volume":"42","author":"Banovac","year":"2004","journal-title":"Spinal Cord"},{"issue":"3","key":"10.1016\/j.injury.2025.112357_bib0033","doi-asserted-by":"crossref","first-page":"256","DOI":"10.5301\/hipint.5000109","article-title":"Effect of a selective COX-2 inhibitor, celecoxib, on heterotopic ossification after total hip arthroplasty: a case-controlled study","volume":"24","author":"Oni","year":"2014","journal-title":"Hip Int"},{"key":"10.1016\/j.injury.2025.112357_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2020.105737","article-title":"Pharmacologic prophylaxis for heterotopic ossification following spinal cord injury: A systematic review and meta-analysi","volume":"193","author":"Yolcu","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"issue":"3","key":"10.1016\/j.injury.2025.112357_bib0035","doi-asserted-by":"crossref","DOI":"10.1590\/1413-785220233103e267451","article-title":"Heterotopic Ossification after Spinal Cord Injury: Prevention and Treatment - a Sistematic Review","volume":"31","author":"Schincariol","year":"2023","journal-title":"Acta Ortop Bras"}],"container-title":["Injury"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0020138325002177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0020138325002177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T08:06:45Z","timestamp":1752566805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0020138325002177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0020138325002177"],"URL":"https:\/\/doi.org\/10.1016\/j.injury.2025.112357","relation":{},"ISSN":["0020-1383"],"issn-type":[{"value":"0020-1383","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of Bisphosphonates in the prevention and treatment of Heterotopic Ossification following Spinal Cord Injury: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Injury","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.injury.2025.112357","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112357"}}